Thiethylperazine Malate
FDA-approved product (injectable, injection), marketed as Torecan.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Phenothiazine derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli45.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae17.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis71.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Thiethylperazine Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- CangrelorExisting use: Myocardial infarction, Percutaneous Coronary Intervention, Recurrent thrombophlebitis45.9% AI-predicted activityagainst E. coli45 registered studies
- IloperidoneExisting use: Psychosis, Schizophrenia45.8% AI-predicted activityagainst E. coli32 registered studies
- Fostamatinib DisodiumExisting use: Autoimmune thrombocytopenic purpura, Hemorrhage, Thrombocytopenia45.7% AI-predicted activityagainst E. coli27 registered studies
- DocetaxelExisting use: Adenocarcinoma, Breast cancer, Breast carcinoma and 19 more45.7% AI-predicted activityagainst E. coli50+ registered studies
- Fedratinib HydrochlorideExisting use: Myelofibrosis, Myeloproliferative disorder, Neoplasm and 1 more45.6% AI-predicted activityagainst E. coliNo documented evidence found
- IvabradineExisting use: Angina pectoris, Cardiovascular disease, Congestive heart failure and 1 more45.5% AI-predicted activityagainst E. coli50+ registered studies
- Pimavanserin TartrateExisting use: Hallucinations, Parkinson disease, Psychosis45.4% AI-predicted activityagainst E. coli46 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis45.2% AI-predicted activityagainst E. coli50+ registered studies
- RescinnamineExisting use: Hypertension45.2% AI-predicted activityagainst E. coliNo documented evidence found
- EluxadolineExisting use: Diarrheal disease, Irritable bowel syndrome45.1% AI-predicted activityagainst E. coli10 registered studies
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis45.0% AI-predicted activityagainst E. coli7 registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease44.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.